SCHEMBL5381685

SCHEMBL5381685

CCc1ccccc1Nc1n[nH]c(SCc2ccccc2OC)n1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
METAP2 P50579 4/20 0.52
SMN1; SMN2 Q16637 1/20 0.48
CTSB P07858 1/20 0.45
GAA P10253 2/20 0.44
KDM1A O60341 1/20 0.44
HSD17B10 Q99714 1/20 0.44
RCOR1 Q9UKL0 1/20 0.44
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
MAPK1 P28482 1/20 0.42
KMT2A Q03164 1/20 0.42
P2RX7 Q99572 2/20 0.40
TSHR P16473 2/20 0.39
ALPL P05186 1/20 0.39
CASP1 P29466 1/20 0.39
EGFR P00533 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5396948 0.92 METAP2 (0.55) METAP2SMN1; SMN2CTSBGAAKDM1A
SCHEMBL5371983 0.89 METAP2 (0.66) METAP2SMN1; SMN2CTSBGAAKDM1A
SCHEMBL5392093 0.86 METAP2 (0.49) METAP2SMN1; SMN2CTSBGAAKDM1A
SCHEMBL5381797 0.86 METAP2 (0.49) METAP2SMN1; SMN2CTSBGAAKDM1A
SCHEMBL5393592 0.85 METAP2 (0.52) METAP2SMN1; SMN2GAAALDH1A1MAPT
SCHEMBL5391683 0.84 NPC1 (0.47) METAP2SMN1; SMN2CTSBGAAMEN1
SCHEMBL5373695 0.84 METAP2 (0.54) METAP2SMN1; SMN2GAAKDM1AHSD17B10
SCHEMBL5380594 0.84 HPGD (0.46) SMN1; SMN2CTSBGAAALDH1A1MEN1
SCHEMBL5376464 0.84 METAP2 (0.50) METAP2SMN1; SMN2CTSBGAAHSD17B10
SCHEMBL5382003 0.84 METAP2 (0.52) METAP2SMN1; SMN2GAAKDM1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7304082-B2 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION (US) 2007-12-04 US disclosed
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use SMITHKLINE BEECHAM CORPORATION 2005-12-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050267185-A1 1,2,4-triazole derivatives, compositions, process of making and methods of use METAP2, METAP1, DNPEP METAP2 1/4885SMN1; SMN2 4773/4885CTSB 178/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.